Amelia Technologies LLC is a rapidly expanding molecular biotechnology company with laboratories and offices located in the Maryland, DC, Virginia biotechnology corridor.

Amelia excels in the development and optimization of molecular diagnostics platforms that measure a range of endpoints associated with DNA damage and repair including general DNA maintenance processes. Currently, Amelia leverages this expertise in four major overlapping areas of research:

Carcinogenesis, aging and associated diseases, genome editing protocols and emerging diagnostics platforms.  Our clients and collaborators include academia, industry and government organizations both here in the United States and abroad.


Amelia strives to provide a confidential platform in which new molecular technology can be further optimized, better developed or adapted to higher through-put detection. We also provide a range of skills and technology to our clients that allow them to more quickly conquer hurdles in methodology that are inhibiting timely development of product.